Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor

Publisher： Karger

E-ISSN： 1423-0232|90|2|112-117

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.2, 2016-0, pp. : 112-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2325-2333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of Imatinib-Resistant CML Patients

By  

Oncology Research and Treatment, Vol. 30, Iss. 11, 2007-10 ,pp. : 574-580

Karger

Access to resources Recommend Favorite

Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 3, 2015-03 ,pp. : 177-184

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib‐induced agranulocytosis in patients with gastrointestinal stromal tumors

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 8, 2015-08 ,pp. : 920-925

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 326-332

Karger

Access to resources Recommend Favorite